MRVT Stock Overview
Operates as a pharmaceutical research and development company. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Miravant Medical Technologies Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 0% |
33 Year Change | -99.97% |
5 Year Change | 0% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
MRVT | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 3.4% | 1.6% |
1Y | 0% | 14.2% | 32.3% |
Return vs Industry: MRVT underperformed the US Pharmaceuticals industry which returned 15.4% over the past year.
Return vs Market: MRVT underperformed the US Market which returned 20.5% over the past year.
Price Volatility
MRVT volatility | |
---|---|
MRVT Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRVT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRVT's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | n/a | n/a | n/a |
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors.
Miravant Medical Technologies Inc. Fundamentals Summary
MRVT fundamental statistics | |
---|---|
Market cap | US$37.00 |
Earnings (TTM) | -US$15.34m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MRVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRVT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$15.34m |
Earnings | -US$15.34m |
Last Reported Earnings
Sep 30, 2005
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did MRVT perform over the long term?
See historical performance and comparison